Evidence map›Paper›PMID 30565753›Full record

ArticleMycoses2019

Cryptococcal meningitis is a cause for cross-reactivity in cerebrospinal fluid assays for anti-Histoplasma, anti-Coccidioides and anti-Blastomyces antibodies.

Nathan C Bahr, Anil A Panackal, Michelle M Durkin, Melinda L Smedema, Wesley Keown, Thomas E Davis, Luke Raymond-Guillen, Yoon-Dong Park, Kieren A Marr, Bettina C Fries and 3 more

Abstract read
In one paragraph

Article in Mycoses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Nathan C BahrDivision of Infectious Diseases, Department of Medicine, University of Kansas, Kansas City, Kansas.ORCID http://orcid.org/0000-0002-9431-8938
Anil A PanackalLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.ORCID http://orcid.org/0000-0001-5524-668X
Michelle M DurkinMiraVista Diagnostics, Indianapolis, Indianapolis, Indiana.
Melinda L SmedemaMiraVista Diagnostics, Indianapolis, Indianapolis, Indiana.
Wesley KeownMiraVista Diagnostics, Indianapolis, Indianapolis, Indiana.
Thomas E DavisDepartment of Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana.
Luke Raymond-GuillenDivision of Infectious Diseases, Department of Medicine, Indiana University, Indianapolis, Indiana.
Yoon-Dong ParkLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Kieren A MarrDivision of Infectious Disease, Department of Medicine Johns Hopkins, Baltimore, Maryland.ORCID http://orcid.org/0000-0002-1051-0376
Bettina C FriesDivision of Infectious Disease, Department of Medicine, Stony Brook School of Medicine, Stony Brook, New York.ORCID http://orcid.org/0000-0002-6847-5518
Peter R WilliamsonLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
David R BoulwareDivision of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.ORCID http://orcid.org/0000-0002-4715-0060
L Joseph WheatMiraVista Diagnostics, Indianapolis, Indianapolis, Indiana.
Indianapolis Zoo · USNational Institutes of Health · USIndiana University Health · USIndiana University – Purdue University Indianapolis · USJohns Hopkins University · USStony Brook School · USUniversity of Kansas · USUniversity of Minnesota · US

Funding

Molecular Pathobiology of Cryptococcus neoformansZIAAI001123 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WILLIAMSON, PETER · 2010 to 2025
$10.4M
Translational Research: Host-Pathogen Interactions in Patient Fungal DiseasesZIAAI001124 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WILLIAMSON, PETER · 2010 to 2025
$8.8M
Trial for the Optimal Timing of HIV Therapy after Cryptococcal MeningitisU01AI089244 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R · 2010 to 2014
$7.6M
Infectious Disease Training in Clinical InvestigationT32AI055433 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI David R Boulware · 2003 to 2026
$6.1M
response to phenotypic switch variants to C. neoformansR01AI059681 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI FRIES, BETTINA · 2004 to 2014
$3.6M
Investigation on Replicative aging in Cryptococcus neoformans populationsR01AI127704 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI FRIES, BETTINA · 2017 to 2021
$3.2M
Prospective Cohort Study of CryptococcosisU01AI109657 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARR, KIEREN A., WILLIAMSON, PETER RICHARD · 2013 to 2015
$1.9M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases AI001123Division of Intramural Research, National Institute of Allergy and Infectious Diseases AI001124Intramural NIH HHS ZIA AI001123Intramural NIH HHS ZIA AI001124National Institute of Allergy and Infectious Diseases RO1AI127704National Institute of Allergy and Infectious Diseases RO1AIO59681National Institute of Allergy and Infectious Diseases T32AI055433National Institute of Allergy and Infectious Diseases U01AI089244National Institute of Allergy and Infectious Diseases UO1AI109657NIAID NIH HHS R01 AI059681NIAID NIH HHS R01 AI127704NIAID NIH HHS T32 AI055433NIAID NIH HHS U01 AI089244NIAID NIH HHS U01 AI109657
6 · The paper itself

Abstract

BACKGROUND/

objectivesAntibody detection is commonly used for diagnosis of histoplasmosis, and cross-reactions have been recognised due to endemic mycoses but not cryptococcosis. We observed cross-reactions in an anti-Histoplasma antibody enzyme immunoassay (EIA) in the cerebrospinal fluid (CSF) from a patient with cryptococcal meningitis and sought to assess the risk of cross-reactive anti-Histoplasma antibodies in persons with cryptococcal meningitis.

methodsAn anti-cryptococcal antibody EIA was developed to measure CSF antibody response in HIV-infected subjects from Kampala, Uganda and previously healthy, HIV-negative subjects at the National Institutes of Health (NIH) with cryptococcal meningitis. Specimens were tested for cross-reactivity in assays for IgG anti-Histoplasma, anti-Blastomyces and anti-Coccidioides antibodies.

resultsAmong 61 subjects with cryptococcal meningitis (44 Kampala cohort, 17 NIH cohort), elevated CSF anti-cryptococcal antibody levels existed in 38% (23/61). Of the 23 CSF specimens containing elevated anti-cryptococcal antibodies, falsely positive results were detected in antibody EIAs for histoplasmosis (8/23, 35%), coccidioidomycosis (6/23, 26%) and blastomycosis (1/23, 4%). Overall, 2% (2/81) of control CSF specimens had elevated anti-cryptococcal antibody detected, both from Indiana.

conclusionsCryptococcal meningitis may cause false-positive results in the CSF for antibodies against Histoplasma, Blastomyces and Coccidioides. Fungal antigen testing should be performed to aid in differentiating true- and false-positive antibody results in the CSF.

Indexed as

Cross ReactionsAdultAntibodies, FungalBlastomycesCerebrospinal FluidCoccidioidesFalse Positive ReactionsHistoplasmaHIV InfectionsHumansMeningitis, CryptococcalProspective StudiesSerologic TestsUgandaUnited StatesAntibodies, Fungalantibody detectionBlastomycosiscoccidioidomycosiscross-reactivityCryptococcosisHistoplasmosis

Identifiers

PMID30565753
PMCPMC6380936
OpenAlexW2904454966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.